‘Unprecedented’ 3-Year Sustained Survival in SCLC With New Combo
The overall survival benefit with durvalumab plus etoposide and cisplatin/carboplatin versus EP alone for the first-line treatment of extensive-stage small […]
(Reuters Health) – Despite adjustments to the U.S. Preventive Services Task Force lung cancer screening criteria, disparities in eligibility between […] Second-line treatment with sintilimab improved survival, when compared with docetaxel, in patients with advanced/metastatic squamous non–small cell lung cancer (sqNSCLC) […] NEW YORK (Reuters Staff) – Using serum metabolomics profiling, researchers have identified two metabolites that are associated with risk for […]lung carcinoma
Revised Guidelines Did Not Reduce Disparities in Lung Cancer Screening Eligibility
Superior Survival With Sintilimab in Squamous NSCLC
Serum Biomarkers of Increased Risk for Second Primary Lung Cancer Identified